Home Latest Articles
Latest Articles
  • Xuesong GAO, Huihui LIU, Xingjun GU
    World Clinical Drug. 2023, 44(5): 483-487.
    Objective

    To investigate the effects of metoprolol combined with tirofiban in the treatment of acute myocardial infarction (AMI) and its effects on serum lipoprotein-associated phospholipase (Lp-PL) A2, growth differentiation factor (GDF)-15 and soluble ST2 protein (sST2).

    Methods

    A total 165 patients with AMI who received treatment in the department of cardiology of Yancheng third people's hospital from January 2020 to June 2022 were selected and divided into experimental group (n=83, metoprolol+tirofiban) and control group (n=82, metoprolol) by random number table method. Clinical efficacy, serum Lp-PLA2, GDF-15, sST2, cardiac output (CO), stroke volume (SV), left ventricular ejection fraction (LVEF), cardiovascular adverse events (CVAE) and incidence of adverse reactions were compared between the two groups.

    Results

    After treatment, the total effective rate of experimental group was higher than that of control group (93.98% vs 82.93%), the difference was statistically significant (P<0.05). Serum Lp-PLA2, GDF-15 and sST2 levels in two groups were decreased over time, and the experimental group was lower than the control group, the difference was statistically significant (P<0.05). The levels of CO, SV and LVEF in both groups were increased over time, and the experimental group was higher than the control group, the difference was statistically significant (P<0.05). The reoccurrence of MI, angina pectoris, heart failure and its severity in experimental group were lower than those in control group, and the difference were statistically significant (P<0.05). There was no statistical significance in the occurrence of adverse reactions between the two groups (P>0.05).

    Conclusion

    Metoprolol combined with tirofiban is effective in AMI patients, which can effectively improve serum Lp-PLA2, GDF-15, sST2 and cardiac function.

  • Xuxia XU, Haoyu LIU, Cuiyun KANG
    World Clinical Drug. 2023, 44(5): 488-492.
    Objective

    To explore the influence of continuous analgesia with fascia iliaca compartment block (FICB) on postoperative pain and early rehabilitation after hip fracture surgery in the elderly.

    Methods

    A total of 103 elderly patients with hip fracture underwent surgical treatment in the Department of Anesthesiology, Luliang People's Hospital from August 2017 to August 2019 were selected and divided into observation group (n=52) and control group (n=51) by random number table method. Both groups were given general anesthesia, the control group was given postoperative intravenous analgesia, and the observation group was given FICB continuous analgesia. The visual analogue scale (VAS), serum cortisol (Cor), angiotensin (Ang) Ⅱ, activities of daily living (ADL) and Harris hip rating scale and complications were compared between the two groups at different time points.

    Results

    The total excellent and good rate of the observation group was 94.23%, which was higher than that of the control group 80.39% (P<0.05). At 4 h and 12 h after surgery, VAS scores in both groups increased with time, and the observation group was lower than those of the control group (P<0.05). At 24 h and 48 h after surgery, VAS scores of both groups were decreased with time, and the observation group was lower than those of the control group (P<0.05). After surgery, the levels of Cor and AngⅡ in both groups were decreased with time, and the observation group were lower than those of the control group (P<0.05). Thirty days after surgery, ADL and Harris scores of both groups were increased with time, and the observation group were higher than those of the control group (P<0.05). The hospitalization time of the observation group was shorter than that in the control group, and the difference was significant (P<0.05). The total incidence of complications in the observation group was lower than that in the control group (7.69% vs 25.49%, P<0.05).

    Conclusion

    The application of FICB for continuous analgesia in elderly patients with hip fracture can help promote postoperative rehabilitation and effectively improve postoperative pain, with fewer complications.

  • Yanhong CHEN, Xingyun HOU, Yongjia YU, Xinyi LU, Ying GAO, Feng ZHANG
    World Clinical Drug. 2023, 44(5): 493-498.
    Objective

    To investigate the correlation between gene polymorphism of cyclophosphamide (CTX) metabolic enzyme and membranous nephropathy (MN), and to provide a basis for individualized drug administration.

    Methods

    The clinical data of 80 MN patients treated with CTX in the department of nephropathy, Shanghai Changzheng hospital from January 2021 to October 2022 were analyzed, and the metabolic enzyme genes of CTX (CYP2C19*2, CYP2C19*3, CYP3A5, GSTP1) were detected. The changes of 24 h urinary protein quantity, serum albumin, creatinine (Cr) and the adverse drug events were observed and analyzed when CTX was used and 1, 3, 6, and 12 months after treatment.

    Results

    The frequency distributions of CYP2C19*2, CYP2C19*3, CYP3A5 and GSTP1 were consistent with Hardy-Weinberg equilibrium distribution. In CYP2C19*2 GA genotype carriers, there were significant difference in 24 h urinary protein, serum albumin and Cr levels compared with those before treatment (P<0.05). In CYP2C19*3 GG, GA and AA genotype carriers, there was no significant difference in 24 h urinary protein, serum albumin and Cr levels compared with those before treatment (P>0.05). In CYP3A5 AG genotype carriers, there was a significant difference in Cr level compared with that before treatment (P<0.05), but there was no significant difference in serum albumin and 24 h urinary protein quantification. In glutathione S-transferase pi-1 AA, AG and GG genotype carriers, there was no significant difference in 24 h urinary protein, serum albumin and Cr levels compared with those before treatment (P>0.05).

    Conclusion

    The gene polymorphism of CTX metabolic enzyme CYP2C19*2 may have a significant effect on the efficacy of MN, and the efficacy of GA genotype carriers is better. The Cr level in CYP3A5 AG genotype carriers is significantly reduced.

  • Yuhui CHU, Yaowu ZUO, Dianfu ZHANG
    World Clinical Drug. 2023, 44(5): 499-505.
    Objective

    To retrospectively analyze the effects of different doses of rivaroxaban on renal function outcome and prognosis in elderly patients with atrial fibrillation (AF) combined with stable coronary artery disease (SCAD).

    Methods

    A total of 416 elderly (≥65 years old) AF-SCAD patients who received rivaroxaban treatment (≥3 months) in our hospital from January to December 2018 were retrospectively analyzed, and divided into low-dose group (<10 mg/d), conventional-dose group (10 - 15 mg/d) and high-dose group (20 mg/d) according to the initial dose. The primary effective end points of treatment included cardiovascular death, myocardial infarction, ischemic stroke/transient ischemic attack, pulmonary embolism and deep venous thrombosis of the lower extremities. The primary safety end points were bleeding events and acute kidney disease (AKD).

    Results

    There were statistically significant differences in baseline creatinine clearance and medication time of rivaroxaban among the three groups (P<0.05). The incidence of AKD in the high-dose group was higher than that in the low-dose group during follow-up (P<0.05). Univariate and multivariate logistic regression analysis showed that after adjusting the time of administration of rivaroxaban and the initial serum creatinine clearance, rivaroxaban 20 mg/d was still an independent risk factor for AKD in patients with AF-SCAD (odds rate=3.579, 95% confidence interval: 1.879 -9.974), and also the independent risk factor for AKD in patients with baseline serum creatinine clearance of 50 - 79ml/min or ≥80ml/min (odds rate=6.876, 95% confidence interval: 2.647 - 14.652, odds rate=2.159, 95% confidence interval: 1.042 - 5.477). In addition, for patients with baseline serum creatinine clearance of 50 - 79ml/min, the conventional dose of rivaroxaban (10 - 15 mg/d) also increase the risk of AKD in patients with AF-SCAD (odds rate=1.254, 95% confidence interval: 1.001 - 1.959).

    Conclusion

    Rivaroxaban 20 mg/d can increases AKD risk in elderly patients with AF-SCAD and received percutaneous coronary intervention.

  • Huili HE, Haiwei ZHANG, Dongdong YUAN, Mengxing LIU
    World Clinical Drug. 2023, 44(5): 506-512.
    Objective

    To evaluate the efficacy of osimertinib mesylate in the treatment of epidermal growth factor receptor (EGFR) mutant non-small cell lung cancer (NSCLC) by Meta analysis.

    Methods

    The literature of randomized controlled trial (RCT) of osimertinib mesylate in the treatment of EGFR mutant NSCLC published in the well-known domestic and foreign databases from the establishment of the database to May 2022 were included, and RevMan5.2 software was used to perform meta-analysis on its effect.

    Results

    A total of 7 articles were included, including 2 reports in Chinese and 5 reports in English, with a total of 2 591 patients. There were 1 385 cases in the experiment group treated with osimertinib mesylate and 1 206 cases in the control group treated with chemotherapy or gefitinib or erlotinib. The quality of the included articles was up to the standard. The literature on clinical benefit rate and total effective rate was heterogeneous (I2=62%, P=0.02; I2=65%, P=0.04). Random effects model analysis showed no significant difference (RR=0.08, 95%CI: -0.12 -0.14, P=0.159; RR=0.04, 95%CI: -0.02 - 0.11, P=0.136). There were no heterogeneity in progression free survival (PSF), overall survival (OS), survival, and median duration of remission (mDOR, I2=41%, P=0.26; I2=36%, P=0.31; I2=25%, P=0.63; I2=18%, P=0.72). The PSF, OS and mDOR in the experiment group were longer than those in the control group (WMD=4.38, 95%CI: 4.25 - 4.46, P<0.001; WMD=3.97, 95%CI: 3.82 - 4.09, P<0.001; WMD=3.36, 95%CI: 3.14~3.58, P<0.001), and the survival rate of the experiment group was higher than that of the control group (WMD=2.57, 95%CI: 2.25 - 2.7, P<0.001). There was no risk of publication bias.

    Conclusion

    Compared with chemotherapy or gefitinib or erlotinib, osimertinib mesylate can prolong PSF, OS, mDOR and improve survival rate in patients with EGFR mutant NSCLC.

  • Menghao ZHAO, Di LI, Guangxin XIA
    World Clinical Drug. 2023, 44(5): 513-520.

    Breast cancer is the first malignant tumor, which seriously threatens women's life and health. HER2-targeted therapies have experienced more than 20 years of development and are important biomarkers affecting the prognosis and treatment strategies of breast cancer. Current guidelines use the combined detection method IHC and ISH to detect HER2 expressions, status in breast cancer. There is a consensus that classifying the HER2-low in negative patients. Anti-HER2 drugs on the market include antibodies, small-molecule drugs and ADCs, which can be used for effective treatment of different expression of HER2. This article reviewed the different expression status of HER2 in breast cancer and the research progress of anti-HER2 drugs.

  • Congying LI, Wei ZHANG
    World Clinical Drug. 2023, 44(4): 301-306.

    Botulinum toxin is a bacterial exotoxin produced by Clostridium botulinum. Due to its strong nerve block and other effects, botulinum toxin has been widely used in the treatment of various diseases and disciplines. Injection of botulinum toxin has become the most popular minimally invasive treatment in recent years in the field of cosmetic dermatology. This article reviewed the mechanism and application progress of botulinum toxin in the treatment and cosmetology of skin diseases, which provided references for further research and clinical application of botulinum toxin.

  • Qingqing XIAO, Yan QIANG, Shangpu GAO, Yu SONG, Bo YANG, Xiaorui LI, Sunsi WU, Xiangpo ZHANG, Xin LI
    World Clinical Drug. 2023, 44(4): 307-311.

    As we age, the body inevitably shows signs of aging, especially in the face, which is manifested as rough skin, obvious wrinkles, poor elasticity, pigmentation, sagging and other signs. According to the performance of facial aging, a variety of methods to improve facial aging have emerged in recent years, whether laser, ultrasound, wrinkle removal surgery, embedding or injection have made remarkable progress, and some of them are combined or upgraded on the traditional single program. This article reviewed the progress of various strategies for facial skin rejuvenation in recent years.

  • Dong DONG, Tianyi LIU
    World Clinical Drug. 2023, 44(4): 312-316.

    With the development of economy and social progress, facial aging has gradually become a hot spot in the field of plastic and aesthetic surgery, and the demand for facial rejuvenation is also growing. However, current studies on facial aging mostly focus on the upper and middle face, while lower face aging is rarely reported. Among them, cheek ptosis is one of the important features of aging lower face, which is characterized by severe relaxation and ptosis of the skin in the lower face area outside the mouth and in front of the mandibular angle, and the accumulation of subcutaneous soft tissue forming a pouch-like appearance resembling the goat's cheek. Because of its serious impact on appearance, it has attracted more and more attention from beauty seekers and plastic surgeons in recent years. This article reviewed the mechanism of cheek ptosis and current treatment strategies, in order to help surgeons better understand the changes of cheek ptosis and aging of the middle and lower face.

  • Shouliang LING, Yan DONG, Manli LEI, Xiaofang WANG
    World Clinical Drug. 2023, 44(4): 317-323.
    Objective

    To investigate the inhibitory effect of tropomyosin receptor kinase a (TrkA) receptor blocker K252a on corneal neovascularization in rats after alkali burn and its related mechanism.

    Methods

    Sixty SD rats were selected to establish the corneal alkali burn model. They were randomly divided into four groups, A, B, C, and D, which were given 50, 100, and 200 nmol/L K252a eye drops and physiological saline eye drops, respectively, twice a day for 14 consecutive days. Corneal neovascularization (CNV) was observed at D3, 7, and 14 after alkali burn. Tumor necrosis factor (TNF)-α in corneal tissue was detected by ELISA. The protein expression levels of nerve growth factor (NGF), extracellular signal-regulated kinase (ERK), and vascular endothelial growth factor (VEGF) were detected by western blotting. The morphological changes of corneal tissue in each group were observed on D14 after alkali burn.

    Results

    At D3, 7, and 14 after alkali burn, the length and area of CNV in group D were larger than those in the other three groups (P<0.05). The level of TNF-α protein in group D was higher than that in other three groups (P<0.05). The protein expressions of NGF, p-ERK and VEGF in group D were higher than those in the other three groups (P<0.05), and the group A to group C showed a dose-dependent decreasing trend. In group D, the upper corneal cortex was thinner, the lumen of neovascularization was dense, a large number of inflammatory cells were infiltrated, and a large number of neovascularization was formed and filled with red blood cells in the stroma layer. The corneal histopathology in group A to group C was better than that in group D, and group C was better than in group A and B.

    Conclusion

    TrkA receptor blocker K252a can reduce the formation of CNV and the level of inflammatory cytokines induced by alkali burn, which may be related to the inhibition of NGF expression and the activation of ERK-VEGF pathway.

News